Skip to main content
. 2024 Feb 3;9:22. doi: 10.1038/s41541-024-00813-3

Fig. 1. HBV mRNA vaccine induced efficient viral suppression and achieved robust seroconversion in pAAV-HBV1.2 mice.

Fig. 1

a Study design. pAAV-HBV1.2-transduced HBV-carrier mice (n = 5/group) were immunized i.m. with 5 μg or 10 μg HBV mRNA vaccines three times at a 1-week interval. HBV-carrier mice administered with PBS were used as control. At day 60, mice were hydrodynamically re-injected with 8 μg pAAV-HBV1.2 plasmids. Sera samples were collected at the indicated time points. b, d Levels of serum HBsAg and c, e anti-HBs Abs were measured at the indicated time points. f Seven days after viral re-exposure, intrahepatic HBV cccDNA, total DNA, total RNA and 3.5-kb RNA were analyzed. g Seven days after viral re-exposure, serum HBV DNA was quantified. h Seven days after viral re-exposure, HBcAg expression in liver tissues was determined by IHC staining (magnification: ×200; scale bar: 100 µm). GAPDH, glyceraldehyde 3-phosphate dehydrogenase; SEM, standard error of the mean. An unpaired, two-tailed Student’s t test was used for statistical analysis. Data are shown as Mean ± SEM. *p ≤ 0.05, **p ≤ 0.01, ****p ≤ 0.0001.